Hal Barron, Endpoints UKBIO20 (Jeff Rumans)

Glax­o­SmithK­line makes big down pay­ment on biotech tar­get­ing 'syn­thet­ic vi­a­bil­i­ty' with start­up fund­ing, pipeline deals

Since join­ing British drug­mak­er Glax­o­SmithK­line in 2018, CSO Hal Bar­ron has pushed to beef up the com­pa­ny’s on­col­o­gy port­fo­lio, tak­ing a par­tic­u­lar eye to “syn­thet­ic lethal­i­ty” dis­cov­ery work. Now, GSK is putting down a big chunk of change on the flip side of the coin — cell vi­a­bil­i­ty — for a range of po­ten­tial ther­a­pies out­side of can­cer.

GSK will co-lead a Se­ries A fi­nanc­ing round with an undis­closed amount of cash for Adres­tia Ther­a­peu­tics, a biotech hop­ing to de­vel­op med­i­cines tar­get­ing the “syn­thet­ic vi­a­bil­i­ty” of dys­func­tion­al or dy­ing cells in a range of ther­a­peu­tic ar­eas, GSK said Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.